Sarcomatoid
CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma
The Journal of Pathology. Clinical Research 2023 February 8 [Link] Shingo Inaguma, Akane Ueki, Jerzy Lasota, Masayuki Komura, Asraful Nahar Sheema, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat, David S Schrump, Raffit Hassan, Markku Miettinen, Satoru Takahashi Abstract Diffuse pleural mesothelioma (PM) is a highly aggressive tumour typically…
Read MoreImmunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
Diagnostics 2023 January [Link] Lina Zuccatosta, Tommaso Bizzarro, Giulio Rossi, Graziana Gallo, Stefano Gasparini, Andrea Ambrosini-Spaltro Abstract (1) Background. In the differential diagnosis between sarcomatoid carcinoma (SC) and sarcomatoid mesothelioma (SM), we aimed to investigate the role of Claudin-4 and BAP1, a panel recently used to distinguish conventional carcinoma from epithelioid mesothelioma. (2) Methods. We…
Read MoreNR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreDiverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8
Cell Immunology 2023 January [Link] Muneo Numasaki, Koyu Ito, Kiyoshi Takagi, Kengo Nagashima, Hirotsugu Notsuda, Hirokazu Ogino, Rika Ando, Yoshihisa Tomioka, Takashi Suzuki, Yoshinori Okada, Yasuhiko Nishioka, Michiaki Unno Abstract In this study, we sought to elucidate the roles of the interleukin (IL)-32β and IL-32γ in mesothelioma cell growth, and vascular endothelial growth factor (VEGF)-A…
Read MoreUsefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study
Lung Cancer 2022 November 19 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima Abstract Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP)…
Read MoreMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT
Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…
Read MoreRhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma
Scientific Reports 2022 November 2 [Link] Takuya Hiratsuka, Takushi Yamamoto, Akihiko Yoshizawa, Shinya Toyokuni, Tatsuaki Tsuruyama Abstract Diagnostic markers of malignant mesothelioma (MM) have been extensively investigated. Immunohistochemistry (IHC) markers, such as calretinin, have been used for pathologic diagnosis. However, more diagnostic markers are required to improve the specificity and sensitivity of pathologic diagnosis. This…
Read MoreComparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
Clinical Lung Cancer 2022 December [Link] Kian C Banks, Stephanie Ossowski, Yun-Yi Hung, Diana S Hsu, Simon K Ashiku, Ashish R Patel, Jeffrey B Velotta, J Marie Suga Abstract Background: Optimal therapy for malignant pleural mesothelioma (MPM) remains unclear. We compared overall survival in patients with MPM after various multimodal treatment regimens including combinations of…
Read MoreButein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells
Cancer Drug Resistance 2022 July 3 [Link] Mario Cioce, Daniela Rutigliano, Annamaria Puglielli, Vito Michele Fazio Abstract Aim: Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly…
Read MoreExpression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Modern Pathology 2022 September 17 [Link] Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G Gray, Luca Ampollini, Joachim G Aerts, Emanuela Felley-Bosco, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan von der…
Read More